HA
LFCR icon

Heartland Advisors’s Lifecore Biomedical LFCR Stock Holding History

Heartland Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-500,000
Closed -$1.89M – 182
2023
Q1 		$1.89M Sell
500,000
-701,900
-58% -$3.91M 0.12% 159
2022
Q4 		$7.79M Sell
1,201,900
-6,950
-0.6% -$57.3K 0.49% 92
2022
Q3 		$10.7M Sell
1,208,850
-4,500
-0.4% -$45.8K 0.8% 36
2022
Q2 		$12.1M Sell
1,213,350
-4,575
-0.4% -$45.3K 0.84% 37
2022
Q1 		$14.1M Sell
1,217,925
-6,690
-0.5% -$74.5K 0.87% 30
2021
Q4 		$13.6M Sell
1,224,615
-5,200
-0.4% -$50.5K 0.8% 32
2021
Q3 		$11.3M Sell
1,229,815
-1,500
-0.1% -$16.3K 0.68% 47
2021
Q2 		$13.9M Sell
1,231,315
-875
-0.1% -$10.1K 0.8% 30
2021
Q1 		$13.1M Sell
1,232,190
-2,500
-0.2% -$28.1K 0.83% 27
2020
Q4 		$13.4M Sell
1,234,690
-2,125
-0.2% -$22K 0.96% 19
2020
Q3 		$12M Buy
1,236,815
+9,483
+0.8% +$90.3K 1.05% 16
2020
Q2 		$9.77M Buy
1,227,332
+3,240
+0.3% +$33.4K 0.87% 29
2020
Q1 		$10.6M Buy
1,224,092
+78,660
+7% +$819K 1.14% 13
2019
Q4 		$13M Buy
1,145,432
+103,200
+10% +$1.1M 0.95% 24
2019
Q3 		$11.3M Buy
1,042,232
+757
+0.1% +$8.24K 0.86% 32
2019
Q2 		$9.76M Buy
1,041,475
+205,775
+25% +$2.08M 0.72% 55
2019
Q1 		$10.3M Sell
835,700
-2,300
-0.3% -$28.1K 0.76% 50
2018
Q4 		$9.92M Sell
838,000
-900
-0.1% -$12.4K 0.82% 39
2018
Q3 		$12.1M Buy
838,900
+23,150
+3% +$320K 0.81% 37
2018
Q2 		$12.2M Hold
815,750
– – 0.8% 37
2018
Q1 		$10.6M Sell
815,750
-32,800
-4% -$431K 0.71% 42
2017
Q4 		$10.7M Sell
848,550
-3,100
-0.4% -$39.2K 0.69% 53
2017
Q3 		$11M Sell
851,650
-51,300
-6% -$676K 0.71% 52
2017
Q2 		$13.4M Sell
902,950
-59,000
-6% -$821K 0.86% 31
2017
Q1 		$11.5M Sell
961,950
-8,350
-0.9% -$106K 0.7% 49
2016
Q4 		$13.4M Buy
970,300
+6,050
+0.6% +$83.8K 0.74% 47
2016
Q3 		$12.9M Sell
964,250
-26,050
-3% -$316K 0.74% 44
2016
Q2 		$10.7M Sell
990,300
-61,800
-6% -$682K 0.6% 58
2016
Q1 		$11M Buy
1,052,100
+115,648
+12% +$1.27M 0.58% 62
2015
Q4 		$11.1M Buy
936,452
+52,509
+6% +$645K 0.44% 81
2015
Q3 		$10.3M Buy
883,943
+153,325
+21% +$2.03M 0.38% 94
2015
Q2 		$10.5M Buy
730,618
+430,618
+144% +$6.21M 0.29% 106
2015
Q1 		$4.18M Hold
300,000
– – 0.1% 179
2014
Q4 		$4.14M Hold
300,000
– – 0.08% 200
2014
Q3 		$3.67M Hold
300,000
– – 0.07% 199
2014
Q2 		$3.75M Buy
300,000
+42,199
+16% +$497K 0.07% 203
2014
Q1 		$2.88M Buy
+257,801
New +$2.83M 0.05% 215

Other funds holding LFCR

GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Heartland Advisors's LFCR Position: Q2 2023 in Review

Heartland Advisors sold out of Lifecore Biomedical (LFCR) in Q2 2023, closing a stake of 500,000 shares — an estimated $1.89M sold.

Heartland Advisors first reported a position in LFCR in Q1 2014 and held it in 37 quarters. The position peaked at $14.1M in Q1 2022. 75 funds tracked by Wall St. Rank hold LFCR as of Q2 2023.

  • Heartland Advisors reported no remaining Lifecore Biomedical position as of Q2 2023 after selling out during the quarter.
  • Heartland Advisors sold 500,000 Lifecore Biomedical shares in Q2 2023, an estimated $1.89M.
  • Heartland Advisors first reported a position in Lifecore Biomedical in Q1 2014 and held it in 37 quarters.
  • Heartland Advisors's Lifecore Biomedical position peaked at $14.1M in Q1 2022.
  • 75 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2023.

Based on Heartland Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.